Mika Derynck
Director/Board Member at ENLIVEN THERAPEUTICS, INC.
Net worth: - $ as of 30/05/2024
Mika Derynck active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Director/Board Member | 22/02/2023 | - |
| Independent Dir/Board Member | 22/02/2023 | - | |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Director/Board Member | 18/01/2022 | - |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Chief Tech/Sci/R&D Officer | - | - |
Career history of Mika Derynck
Training of Mika Derynck
| Boston University | Undergraduate Degree |
| Boston University School of Medicine | Doctorate Degree |
Statistics
International
| United States | 5 |
| Israel | 2 |
Operational
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Independent Dir/Board Member | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
- Stock Market
- Insiders
- Mika Derynck
- Experience
